Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Mar 21;61(4):392-398.
doi: 10.1136/jmg-2023-109549.

Risk-reducing decisions regarding germline BRCA pathogenic variant: focusing on the timing of genetic testing and RRSO

Akiko Abe  1 , Hidetaka Nomura  2 , Atsushi Fusegi  2 , Mayu Yunokawa  2 , Arisa Ueki  2 , Eri Habano  2 , Hiromi Arakawa  2 , Keika Kaneko  2 , Yuko Minoura  2 , Hitoshi Inari  2 , Takayuki Ueno  2 , Hiroyuki Kanao  2
Affiliations

Risk-reducing decisions regarding germline BRCA pathogenic variant: focusing on the timing of genetic testing and RRSO

Akiko Abe et al. J Med Genet. .

Abstract

Background: In Japan, the public insurance policy was revised in 2020 to cover hereditary breast and ovarian cancer (HBOC), including genetic testing and surveillance, for patients with breast cancer (BC). Consequently, the demand for risk-reducing salpingo-oophorectomy (RRSO) has increased. This study aimed to clarify the changes in the demand and timing of genetic testing and RRSO associated with public insurance coverage for HBOC in Japan.

Methods: This retrospective analysis included 350 women with germline BRCA (gBRCA) pathogenic variants (PVs) who had visited gynaecologists; they received gBRCA genetic testing at 45.1±10.6 (20-74) years. The use of medical testing and preventive treatment was compared between the preinsurance and postinsurance groups using Mann-Whitney U and Fisher's exact tests.

Results: The findings indicate that RRSO rates doubled from 31.4% to 62.6% among patients with gBRCA-PV. The implementation rate was 32.4% among unaffected carriers and 70.3% among BC-affected patients. Younger patients received genetic testing with significantly shorter intervals between BC diagnosis and genetic testing and between genetic testing and RRSO.

Conclusion: Overall, the insurance coverage for HBOC patients with BC has increased the frequency of RRSO in Japan. However, a comparison between the number of probands and family members indicated that the diagnosis among family members is inadequate. The inequality in the use of genetic services by socioeconomic groups is an issue of further concern.

Keywords: women's health services.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

Figures

Figure 1
Figure 1
Flow diagram of participants. In total, 531 carriers of BRCA1/2 pathogenic variants were identified. PV, pathogenic variant; RRSO, risk-reducing salpingo-oophorectomy.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Miki Y, Swensen J, Shattuck-Eidens D, et al. . A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994;266:66–71. 10.1126/science.7545954 - DOI - PubMed
    1. Wooster R, Bignell G, Lancaster J, et al. . Identification of the breast cancer susceptibility gene BRCA2. Nature 1995;378:789–92. 10.1038/378789a0 - DOI - PubMed
    1. Siegel RL, Miller KD, Fuchs HE, et al. . Cancer statistics, 2021. CA Cancer J Clin 2021;71:7–33. 10.3322/caac.21654 - DOI - PubMed
    1. Colombo P-E, Fabbro M, Theillet C, et al. . Sensitivity and resistance to treatment in the primary management of epithelial ovarian cancer. Crit Rev Oncol Hematol 2014;89:207–16. 10.1016/j.critrevonc.2013.08.017 - DOI - PubMed
    1. Hirasawa A, Imoto I, Naruto T, et al. . Prevalence of pathogenic germline variants detected by multigene sequencing in Unselected Japanese patients with ovarian cancer. Oncotarget 2017;8:112258–67. 10.18632/oncotarget.22733 - DOI - PMC - PubMed

Supplementary concepts